Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 14, 2015

Primary Completion Date

May 28, 2020

Study Completion Date

May 28, 2020

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

PF-06747775

DRUG

Palbociclib

DRUG

Avelumab

Trial Locations (15)

2050

Chris O'Brien Lifehouse, Camperdown

Royal Prince Alfred Hospital, Camperdown

4032

Prince Charles Hospital, Cancer Care Services, Chermside

15232

UPMC Cancer Pavilion, Pittsburgh

UPMC Hillman Cancer Center, Pittsburgh

92037

UC San Diego Medical Center - La Jolla, La Jolla

92093

UC San Diego Moores Cancer Center, La Jolla

92103

UC San Diego Medical Center - Hillcrest, San Diego

98109

Seattle Cancer Care Alliance, Seattle

06510

Smilow Cancer Hospital at Yale-New Haven, New Haven

791-0280

National Hospital Organization Shikoku Cancer Center, Matsuyama

135-8550

The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo

03080

Seoul National University Hospital / Department of Internal Medicine, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY